CSIMarket


Amphastar Pharmaceuticals Inc   (NASDAQ: AMPH)
Other Ticker:  
 

Amphastar Pharmaceuticals Inc

AMPH's Fundamental analysis








Looking into Amphastar Pharmaceuticals Inc growth rates, revenue grew by 4.32 % in IV. Quarter 2024 from the same quarter a year ago. Ranking at No. 645

Major Pharmaceutical Preparations industry recorded growth of revenues by 11.85 %

Amphastar Pharmaceuticals Inc 's net profit decreased by -45.77 % in IV. Quarter 2024 year on year, to $27 millions.

More on AMPH's Growth


Amphastar Pharmaceuticals Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Amphastar Pharmaceuticals Inc PEG ratio is at 0.73 Amphastar Pharmaceuticals Inc realized cash reduction of $ -2.29 per share in trailing twelve-month period.
Company
8.36
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 1.68.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.


More on AMPH's Valuation
 
 Total Debt (Millions $) 602
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 414,262
 Net Income/Employee (TTM) $ 83,171
 Receivable Turnover (TTM) 5.52
 Tangible Book Value (Per Share $) 2.72

Amphastar Pharmaceuticals Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Amphastar Pharmaceuticals Inc PEG ratio is at 0.73 Amphastar Pharmaceuticals Inc realized cash outflow of $ -2.29per share in trailing twelve-month period.
Company
8.36
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 1.68.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.

Amphastar Pharmaceuticals Inc Price to Book Ratio is at 1.67 lower than Industry Avg. of 77.28. and higher than S&P 500 Avg. of 0.01

More on AMPH's Valuation

  Market Capitalization (Millions $) 1,225
  Shares Outstanding (Millions) 52
  Employees 1,761
  Revenues (TTM) (Millions $) 730
  Net Income (TTM) (Millions $) 146
  Cash Flow (TTM) (Millions $) -119
  Capital Exp. (TTM) (Millions $) -50
  Total Debt (Millions $) 602
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 414,262
  Net Income/Employee(TTM) $ 83,171
  Receivable Turnover Ratio (TTM) 5.52
  Tangible Book Value (Per Share $) 2.72

  Market Capitalization (Millions $) 1,225
  Shares Outstanding (Millions) 52
  Employees 1,761
  Revenues (TTM) (Millions $) 730
  Net Income (TTM) (Millions $) 146
  Cash Flow (TTM) (Millions $) -119
  Capital Exp. (TTM) (Millions $) -50


    AMPH's Profitability Comparisons
Amphastar Pharmaceuticals Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in IV. Quarter 2024 to 14.7 % from 29.83 % in III. Quarter.

Amphastar Pharmaceuticals Inc net profit margin of 14.17 % is currently ranking no. 40 in Major Pharmaceutical Preparations industry, ranking no. 95 in Healthcare sector and number 1090 in S&P 500.


Profitability by Segment
Total 21.14 %



  Ratio
   Capital Ratio (MRQ) 3.07
  Total Debt to Equity (MRQ) 0.82
  Tangible Leverage Ratio (MRQ) 5.97
  Asset Turnover Ratio (TTM) 0.47
  Inventory Turnover Ratio (TTM) 2.91



Amphastar Pharmaceuticals Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in IV. Quarter 2024 to 14.7 % from 29.83 % in III. Quarter.

Amphastar Pharmaceuticals Inc net profit margin of 14.17 % is currently ranking no. 40 in Major Pharmaceutical Preparations industry, ranking no. 95 in Healthcare sector and number 1090 in S&P 500.

More on AMPH's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com